Search

OBJECTIVE: To scientifically evaluate the economics of Longshengzhi capsules in the treatment of cerebral infarction (Qi deficiency and blood stasis syndrome) based on cost-effectiveness analysis, so as to provide reference for clinical drug use, academic promotion and decision-making of national pharmaceutical management departments. METHODS: From the perspective of health system, based on the evidence-based medical evidence of the safety and efficacy of Longshengzhi capsules in the treatment of cerebral infarction (Qi deficiency and blood stasis syndrome), the decision tree model of Longshengzhi capsules in the treatment of cerebral infarction was constructed by TreeAge Pro software. Economics of Longshengzhi capsules combined with conventional treatment in patients with cerebral infarction were explored. RESULTS: Combined with evidence-based medicine, drug instructions, drug nonclinical safety studies, and pharmacological and pharmacodynamic studies, it was shown that Longshengzhi capsules were safe in the treatment of patients with cerebral infarction. Meta-analysis of effectiveness of Longshengzhi capsules in the treatment of cerebral infarction showed that Longshengzhi capsules combined with conventional western medicine was superior to conventional western medicine alone in improving the National Institutes of Health Stroke Scale (NIHSS) score, quality of life score and serum homocysteine level in patients with cerebral infarction. Based on the above safety and efficacy evidence, the economic decision tree model simulation results showed that the incremental cost-effectiveness ratio of Longshengzhi capsules combined with conventional western medicine in improving the NIHSS score of patients with cerebral infarction was 238. 84 yuan / point, accounting for 0. 74% of per capita disposable income in 2020 in China ( 32 189 yuan), which had good economy. The result verified to be relatively stable. CONCLUSIONS: Longshengzhi capsules combined with conventional western medicine is more economical than conventional western medicine in improving the NIHSS score of patients with cerebral infarction (Qi deficiency and blood stasis syndrome). [ABSTRACT FROM AUTHOR]